Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors

Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of \[14C\]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.